However, despite the positive data in preclinical models, the clinical activity in advanced prostate cancer patients was modest or not significant (119, 140–142), suggesting that anti-IL-6 therapies may not be the most effective approach to block STAT3 signaling in this setting. The gene discussed is STAT3; the disease is prostate carcinoma.